(S)-Sabutoclax
Based on 1 Customer Validation
(S)-Sabutoclax ((S)-BI-97C1), an optically pure apogossypol derivative, is pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. (S)-Sabutoclax (Compound II) inhibits the binding of BH3 peptides to Bcl-XL, Bcl-2, Mcl-1, and Bfl-1 with IC50 values of 0.31, 0.32, 0.20, and 0.62 μM, respectively. (S)-Sabutoclax also potently inhibits cell growth of human prostate cancer, lung cancer, and lymphoma cell lines with EC50 values of 0.13, 0.56, and 0.049 μM, respectively. (S)-Sabutoclax can be used for the research of apoptosis-based therapies against cancer.
For research use only. We do not sell to patients.
- Purity: 98.03%
- CAS No.: 1228178-73-1
- Formula: C42H40N2O8
- Molecular Weight:700.78
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Blood Cancer Compound Library
HY-L079
-
Mitochondria-Targeted Compound Library
HY-L089
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
IC50: 0.31 μM (Bcl-XL), 0.32 μM (Bcl-2), 0.20 μM (Mcl-1), 0.62 μM (Bfl-1); EC50: 0.13 (human prostate cancer cell lines), 0.56 (lung cancer cell lines), 0.049 μM (lymphoma cell lines)[1].
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H460 | EC50 |
0.42 μM
Compound: (R,-,R)-11, atropisoer
|
Cytotoxicity against human H460 cells after 3 days by ATP-LITE assay
Cytotoxicity against human H460 cells after 3 days by ATP-LITE assay
|
[PMID: 20443627] |
| NCI-H460 | EC50 |
0.78 μM
Compound: (R, +, R)-12
|
Cytotoxicity against human H460 cells after 3 days by ATP-LITE assay
Cytotoxicity against human H460 cells after 3 days by ATP-LITE assay
|
[PMID: 20443627] |
| PC-3 | EC50 |
0.13 μM
Compound: (R,-,R)-11, atropisoer
|
Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay
Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay
|
[PMID: 20443627] |
| PC-3 | EC50 |
4.64 μM
Compound: (R, +, R)-12
|
Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay
Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay
|
[PMID: 20443627] |
Chemical Information
-
CAS No. 1228178-73-1
-
Appearance Solid
-
Molecular Weight 700.78
-
Formula C42H40N2O8
-
Color Light yellow to brown
-
SMILES
O=C(C1=C(O)C(O)=CC2=C(O)[C@]([C@]3=C(C)C=C4C(C(NC[C@@H](C5=CC=CC=C5)C)=O)=C(O)C(O)=CC4=C3O)=C(C)C=C12)NC[C@@H](C6=CC=CC=C6)C
-
Synonyms
(S)-BI-97C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 30 mg/mL (42.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 3 mg/mL (4.28 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 3 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4270 mL | 7.1349 mL | 14.2698 mL | 35.6745 mL |
| 5 mM | 0.2854 mL | 1.4270 mL | 2.8540 mL | 7.1349 mL | |
| 10 mM | 0.1427 mL | 0.7135 mL | 1.4270 mL | 3.5675 mL | |
| 15 mM | 0.0951 mL | 0.4757 mL | 0.9513 mL | 2.3783 mL | |
| 20 mM | 0.0713 mL | 0.3567 mL | 0.7135 mL | 1.7837 mL | |
| 25 mM | 0.0571 mL | 0.2854 mL | 0.5708 mL | 1.4270 mL | |
| 30 mM | 0.0476 mL | 0.2378 mL | 0.4757 mL | 1.1892 mL | |
| 40 mM | 0.0357 mL | 0.1784 mL | 0.3567 mL | 0.8919 mL |
(S)-Sabutoclax Related Classifications
HY-15191B Related Classifications
Powered by Bioz